Target Information

General Information of This Target
Target ID
PATR0QBNMQ
Target Name
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Gene Name
POLR2B; POLR3G
Gene ID
5431 ; 10622
Synonym 1
DNA-directed RNA polymerase II 140 kDa polypeptide; DNA-directed RNA polymerase II subunit B; RNA polymerase II subunit 2; RNA polymerase II subunit B2
Synonym 2
DNA-directed RNA polymerase III subunit G; RNA polymerase III 32 kDa apha subunit; RNA polymerase III 32 kDa subunit
Sequence 1
MYDADEDMQYDEDDDEITPDLWQEACWIVISSYFDEKGLVRQQLDSFDEFIQMSVQRIVE
DAPPIDLQAEAQHASGEVEEPPRYLLKFEQIYLSKPTHWERDGAPSPMMPNEARLRNLTY
SAPLYVDITKTVIKEGEEQLQTQHQKTFIGKIPIMLRSTYCLLNGLTDRDLCELNECPLD
PGGYFIINGSEKVLIAQEKMATNTVYVFAKKDSKYAYTGECRSCLENSSRPTSTIWVSML
ARGGQGAKKSAIGQRIVATLPYIKQEVPIIIVFRALGFVSDRDILEHIIYDFEDPEMMEM
VKPSLDEAFVIQEQNVALNFIGSRGAKPGVTKEKRIKYAKEVLQKEMLPHVGVSDFCETK
KAYFLGYMVHRLLLAALGRRELDDRDHYGNKRLDLAGPLLAFLFRGMFKNLLKEVRIYAQ
KFIDRGKDFNLELAIKTRIISDGLKYSLATGNWGDQKKAHQARAGVSQVLNRLTFASTLS
HLRRLNSPIGRDGKLAKPRQLHNTLWGMVCPAETPEGHAVGLVKNLALMAYISVGSQPSP
ILEFLEEWSMENLEEISPAAIADATKIFVNGCWVGIHKDPEQLMNTLRKLRRQMDIIVSE
VSMIRDIREREIRIYTDAGRICRPLLIVEKQKLLLKKRHIDQLKEREYNNYSWQDLVASG
VVEYIDTLEEETVMLAMTPDDLQEKEVAYCSTYTHCEIHPSMILGVCASIIPFPDHNQSP
RNTYQSAMGKQAMGVYITNFHVRMDTLAHVLYYPQKPLVTTRSMEYLRFRELPAGINSIV
AIASYTGYNQEDSVIMNRSAVDRGFFRSVFYRSYKEQESKKGFDQEEVFEKPTRETCQGM
RHAIYDKLDDDGLIAPGVRVSGDDVIIGKTVTLPENEDELESTNRRYTKRDCSTFLRTSE
TGIVDQVMVTLNQEGYKFCKIRVRSVRIPQIGDKFASRHGQKGTCGIQYRQEDMPFTCEG
ITPDIIINPHAIPSRMTIGHLIECLQGKVSANKGEIGDATPFNDAVNVQKISNLLSDYGY
HLRGNEVLYNGFTGRKITSQIFIGPTYYQRLKHMVDDKIHSRARGPIQILNRQPMEGRSR
DGGLRFGEMERDCQIAHGAAQFLRERLFEASDPYQVHVCNLCGIMAIANTRTHTYECRGC
RNKTQISLVRMPYACKLLFQELMSMSIAPRMMSV

    Click to Show/Hide
Sequence 2
MAGNKGRGRAAYTFNIEAVGFSKGEKLPDVVLKPPPLFPDTDYKPVPLKTGEGEEYMLAL
KQELRETMKRMPYFIETPEERQDIERYSKRYMKVYKEEWIPDWRRLPREMMPRNKCKKAG
PKPKKAKDAGKGTPLTNTEDVLKKMEELEKRGDGEKSDEENEEKEGSKEKSKEGDDDDDD
DAAEQEEYDEEEQEEENDYINSYFEDGDDFGADSDDNMDEATY

    Click to Show/Hide
Family
the RNA polymerase beta chain family; the eukaryotic RPC7 RNA polymerase subuni
Function 1
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Second largest component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Proposed to contribute to the polymerase catalytic activity and forms the polymerase active center together with the largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB2 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template.

    Click to Show/Hide
Function 2
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Specific peripheric component of RNA polymerase III which synthesizes small RNAs, such as 5S rRNA and tRNAs. May direct with other members of the RPC3/POLR3C-RPC6/POLR3F-RPC7/POLR3G subcomplex RNA Pol III binding to the TFIIIB-DNA complex via the interactions between TFIIIB and POLR3F. May be involved either in the recruitment and stabilization of the subcomplex within RNA polymerase III, or in stimulating catalytic functions of other subunits during initiation. Plays a key role in sensing and limiting infection by intracellular bacteria and DNA viruses. Acts as nuclear and cytosolic DNA sensor involved in innate immune response. Can sense non-self dsDNA that serves as template for transcription into dsRNA. The non-self RNA polymerase III transcripts, such as Epstein-Barr virus-encoded RNAs (EBERs), induce type I interferon and NF- Kappa-B through the RIG-I pathway

    Click to Show/Hide
Uniprot Entry
RPB2_HUMAN ; RPC7_HUMAN
HGNC ID
HGNC:9188 ; HGNC:30075
KEGG ID
hsa:5431 ; hsa:10622
Full List of The ADC Related to This Target
Phase 2
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
 ADC Info 
HDP-101
J22.9-ISY
TNFRSF17
HDP 30.2115
Mal-Val-Ala-PAB
 [1]
 ADC Info 
MGTA-117
Undisclosed
KIT
Alpha-amanitin
Undisclosed
 [2]
Clinical candidate
Click To Hide/Show 7 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
 ADC Info 
CD19-ATAC
Undisclosed
CD19
HDP 30.2115
Mal-Val-Ala-PAB
 [3]
 ADC Info 
Trastuzumab-ATAC
Trastuzumab
ERBB2
Alpha-amanitin
Undisclosed
 [4]
 ADC Info 
H14A043-ATAC
Human Anti-CDCP1 h14A043-ATAC mAb
CDCP1
Alpha-amanitin
Undisclosed
 [5]
 ADC Info 
TAK-ATACs
Undisclosed
Undisclosed
Alpha-amanitin
Undisclosed
 [6]
 ADC Info 
HDP-102
Undisclosed
CD37
Alpha-amanitin
Undisclosed
 [7]
 ADC Info 
Antibody targeted amanitin conjugate
Undisclosed
Undisclosed
Alpha-amanitin
Undisclosed
 [8]
 ADC Info 
HDP-103
Undisclosed
FOLH1
Alpha-amanitin
Undisclosed
 [9]
Investigative
Click To Hide/Show 85 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
 ADC Info 
T-D265C-CN-Pro-amanitin
Trastuzumab D265C
ERBB2
CN-Pro-dideoxy-alpha-amanitin
Mal-Val-Ala-PAB
 [10]
 ADC Info 
T-D265C-NH2-Pro-amanitin
Trastuzumab D265C
ERBB2
NH2-Pro-dideoxy-alpha-amanitin
Mc-Val-Ala-PABC
 [10]
 ADC Info 
T-D265C-OH-Pro-amanitin
Trastuzumab D265C
ERBB2
OH-Pro-dideoxy-alpha-amanitin
Mc-Val-Ala-PABC
 [10]
 ADC Info 
Ab85 D265C/H435A ADC A
Ab85 D265C/H435A
CD2
Amaninamide (thioether)
Mc-Val-Ala-PABC
 [11]
 ADC Info 
CD2 RPA2.10 D265C/H435A ADC A
CD2 RPA2.10 D265C/H435A
CD2
Amaninamide (thioether)
Mc-Val-Ala-PABC
 [11]
 ADC Info 
CD2 RPA2.10 D265C/H435A ADC C
CD2 RPA2.10 D265C/H435A
CD2
Alpha-amanitin (thioether)
Maleimido-caproyl
 [11]
 ADC Info 
CD5 5D7 D265C/H435A ADC A
CD5 5D7 D265C/H435A
CD5
Amaninamide (thioether)
Mc-Val-Ala-PABC
 [11]
 ADC Info 
CD5 5D7 D265C/H435A ADC C
CD5 5D7 D265C/H435A
CD5
Alpha-amanitin (thioether)
Maleimido-caproyl
 [11]
 ADC Info 
HuMAB-5B1-ATAC
MVT-5873
Undisclosed
Alpha-amanitin
Undisclosed
 [12]
 ADC Info 
HuMAB 5B1 targeted amanitin conjugate
5B1
Undisclosed
Alpha-amanitin
Undisclosed
 [13]
 ADC Info 
Alpha-amanitin antibody-drug conjugate (Agensys)
Undisclosed
Undisclosed
Alpha-amanitin
Undisclosed
 [14]
 ADC Info 
OHPAS ADC-1
Trastuzumab
ERBB2
Alpha-amanitin
Ortho-hydroxy-protected aryl sulfate
 [15]
 ADC Info 
Anti-HER2-D265C-30.2060
Anti-HER2-D265C
ERBB2
Amanitin 30.206
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-HER2-D265C-30.2115
Anti-HER2-D265C
ERBB2
Amanitin 30.2115
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-HER2-D265C-30.2347
Anti-HER2-D265C
ERBB2
Amanitin 30.2347
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-HER2-D265C-30.1699
Anti-HER2-D265C
ERBB2
Amanitin 30.1699
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-HER2-D265C-30.2371
Anti-HER2-D265C
ERBB2
Amanitin 30.2371
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-HER2-D265C-30.0880
Anti-HER2-D265C
ERBB2
Amanitin 30.088
Maleimido-caproyl
 [11]
 ADC Info 
Anti-HER2-D265C-30.2867
Anti-HER2-D265C
ERBB2
Amanitin 30.2867
Maleimido-caproyl
 [11]
 ADC Info 
Anti-PSMA-D265C-30.2060
Anti-PSMA-D265C
FOLH1
Amanitin 30.206
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-PSMA-D265C-30.2115
Anti-PSMA-D265C
FOLH1
Amanitin 30.2115
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-PSMA-D265C-30.2347
Anti-PSMA-D265C
FOLH1
Amanitin 30.2347
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-PSMA-D265C-30.1699
Anti-PSMA-D265C
FOLH1
Amanitin 30.1699
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-PSMA-D265C-30.2371
Anti-PSMA-D265C
FOLH1
Amanitin 30.2371
Mc-Val-Ala-PABC
 [11]
 ADC Info 
Anti-PSMA-D265C-30.0880
Anti-PSMA-D265C
FOLH1
Amanitin 30.088
Maleimido-caproyl
 [11]
 ADC Info 
Anti-PSMA-D265C-30.2867
Anti-PSMA-D265C
FOLH1
Amanitin 30.2867
Maleimido-caproyl
 [11]
 ADC Info 
T (Anti-HER2)-30.2060
Trastuzumab
ERBB2
Amanitin 30.206
Mc-Val-Ala-PABC
 [11]
 ADC Info 
h3/F11-Var16 (Anti-PSMA)-30.2060
Anti-PSMA mAb h3/F11-Var16
FOLH1
Amanitin 30.206
Mc-Val-Ala-PABC
 [11]
 ADC Info 
T (Anti-HER2)-30.2867
Trastuzumab
ERBB2
Amanitin 30.2867
Maleimido-caproyl
 [11]
 ADC Info 
h3/F11-Var16 (Anti-PSMA)-30.2867
Anti-PSMA mAb h3/F11-Var16
FOLH1
Amanitin 30.2867
Maleimido-caproyl
 [11]
 ADC Info 
LCB14-alpha-amanitin
Anti-CD19 mAb DI-B4
CD19
Alpha-amanitin
LCB14-alpha-amanitin linker
 [16]
 ADC Info 
Anti-CD19(LC)-G7VIM-amanitin
DI-B4-(LC)-GGGGGGG-CVIM
CD19
Alpha-amanitin
Anti-CD19(LC)-G7VIM-amanitin linker
 [16]
 ADC Info 
Blinatumomab-amanitin
Blinatumomab
CD19; CD3D
Alpha-amanitin
Blinatumomab-amanitin linker
 [16]
 ADC Info 
Inebilizumab-amanitin
Inebilizumab
CD19
Alpha-amanitin
Inebilizumab-amanitin linker
 [16]
 ADC Info 
Tafasitamab-amanitin
Tafasitamab
CD19
Alpha-amanitin
Tafasitamab-amanitin linker
 [16]
 ADC Info 
Obexelimab-amanitin
Obexelimab
CD19
Alpha-amanitin
Obexelimab-amanitin linker
 [16]
 ADC Info 
MDX-1342-amanitin
MDX-1342
CD19
Alpha-amanitin
MDX-1342-amanitin linker
 [16]
 ADC Info 
MDX-1435-amanitin
MDX-1435
CD19
Alpha-amanitin
MDX-1435-amanitin linker
 [16]
 ADC Info 
cHD37-amanitin
cHD37
CD19
Alpha-amanitin
cHD37-amanitin linker
 [16]
 ADC Info 
AFM-11-amanitin
AFM-11
CD19
Alpha-amanitin
AFM-11-amanitin linker
 [16]
 ADC Info 
AFM-12-amanitin
AFM-12
CD19
Alpha-amanitin
AFM-12-amanitin linker
 [16]
 ADC Info 
GBR401-amanitin
GBR401
CD19
Alpha-amanitin
GBR401-amanitin linker
 [16]
 ADC Info 
Denintuzumab-amanitin
Denintuzumab
CD19
Alpha-amanitin
Denintuzumab-amanitin linker
 [16]
 ADC Info 
Cetuximab (LC) G7-CVIM-amanitin
Cetuximab (LC) G7-CVIM
EGFR
Alpha-amanitin
Cetuximab(LC) G7-CVIM-amanitin linker
 [17]
 ADC Info 
Cetuximab (LV) G7-CVIM-amanitin
Cetuximab (LV) G7-CVIM
EGFR
Alpha-amanitin
Cetuximab(LV) G7-CVIM-amanitin linker
 [17]
 ADC Info 
Cetuximab (LC)-amanitin
Cetuximab (LC)
EGFR
Alpha-amanitin
Cetuximab(LC)-amanitin linker
 [17]
 ADC Info 
WO2017089895A1 ADC21
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089895A1_ADC21 linker
 [18]
 ADC Info 
WO2017089895A1 ADC22
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089895A1_ADC22 linker
 [18]
 ADC Info 
WO2017089895A1 ADC56
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089895A1_ADC56 linker
 [18]
 ADC Info 
WO2017089895A1 ADC57
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089895A1_ADC57 linker
 [18]
 ADC Info 
huHEA125-amanitin1
huHEA125
EPCAM
Beta-amanitin
huHEA125-Amanitin1 linker
 [19]
 ADC Info 
Omalizumab-amanitin 1
Omalizumab
FCER1A
Beta-amanitin
Omalizumab-Amanitin1 linker
 [19]
 ADC Info 
Trastuzumab-amanitin 1
Trastuzumab
ERBB2
Beta-amanitin
Trastuzumab-Amanitin1 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 3
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 3 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 3
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 3 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 3
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 3 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 4
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 4 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 4
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 4 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 4
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 4 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 7
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 7 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 7
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 7 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 7
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 7 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 10
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 10 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 10
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 10 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 10
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 10 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 11
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 11 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 11
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 11 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 11
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 11 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 14
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 14 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 14
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 14 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 14
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 14 linker
 [19]
 ADC Info 
Trastuzumab-alpha-amanitin conjugate 15
Trastuzumab
ERBB2
Alpha-amanitin
Trastuzumab-alpha-amanitin conjugate 15 linker
 [19]
 ADC Info 
huHEA125-alpha-amanitin conjugate 15
huHEA125
EPCAM
Alpha-amanitin
huHEA125-alpha-amanitin conjugate 15 linker
 [19]
 ADC Info 
Omalizumab-alpha-amanitin conjugate 15
Omalizumab
FCER1A
Alpha-amanitin
Omalizumab-alpha-amanitin conjugate 15 linker
 [19]
 ADC Info 
huHEA125-amanitin3
huHEA125
EPCAM
Beta-amanitin
huHEA125-Amanitin3 linker
 [19]
 ADC Info 
Omalizumab-amanitin 3
Omalizumab
FCER1A
Beta-amanitin
Omalizumab-Amanitin3 linker
 [19]
 ADC Info 
Trastuzumab-amanitin 3
Trastuzumab
ERBB2
Beta-amanitin
Trastuzumab-Amanitin3 linker
 [19]
 ADC Info 
huHEA125-amanitin4
huHEA125
EPCAM
Beta-amanitin
huHEA125-Amanitin4 linker
 [19]
 ADC Info 
Omalizumab-amanitin 4
Omalizumab
FCER1A
Beta-amanitin
Omalizumab-Amanitin4 linker
 [19]
 ADC Info 
Trastuzumab-amanitin 4
Trastuzumab
ERBB2
Beta-amanitin
Trastuzumab-Amanitin4 linker
 [19]
 ADC Info 
Her-30.0643
Trastuzumab
ERBB2
HDP 30.0643
Her-30.0643 linker
 [20]
 ADC Info 
WO2017089890A1 ADC21
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089890A1_ADC21 linker
 [21]
 ADC Info 
WO2017089890A1 ADC22
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089890A1_ADC22 linker
 [21]
 ADC Info 
WO2017089890A1 ADC56
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089890A1_ADC56 linker
 [21]
 ADC Info 
WO2017089890A1 ADC57
Trastuzumab
ERBB2
Alpha-amanitin
WO2017089890A1_ADC57 linker
 [21]
References
Ref 1 HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. Mol Cancer Ther. 2021 Feb;20(2):367-378.
Ref 2 TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) TPS3156-TPS3156.
Ref 3 CD19 - a potential target for Amanitin-based ADCs. Cancer Res (2017) 77 (13_Supplement): 62.
Ref 4 Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023 Jan 17;16(1):3. doi: 10.1186/s13045-022-01397-y.
Ref 5 Antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rapid internalization showed high efficacy for solid cancer. Cancer Res (2023) 83 (7_Supplement): 438.
Ref 6 Heidelberg pharma ATACs fighting cancer; 2020
Ref 7 Introduction to basic information on ADC drug by Heidelberg-pharma.
Ref 8 Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo. Cancer Res (2021) 81 (13_Supplement): 921.
Ref 9 Heidelberg pharma product pipeline
Ref 10 Design, Synthesis, and Biochemical Evaluation of Alpha-Amanitin Derivatives Containing Analogs of the trans-Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates. Chemistry. 2021 Jul 16;27(40):10282-10292. doi: 10.1002/chem.202101373. Epub 2021 Jun 18.
Ref 11 Amatoxin antibody-drug conjugates and uses thereof; 2020-10-29.
Ref 12 Heidelberg pharma: expanding the ADC landscape with a new payload targeting RNA polymerase 2; 2017
Ref 13 Heidelberg pharma: ATACing cancer; 2017
Ref 14 Introduction to basic information on alpha-amanitin antibody-drug conjugates(Agensys).
Ref 15 Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker. Bioconjug Chem. 2019 Jul 17;30(7):1957-1968. doi: 10.1021/acs.bioconjchem.9b00340. Epub 2019 Jun 28.
Ref 16 Compositions and methods related to anti-cd19 antibody drug conjugates; 2017-03-30.
Ref 17 Compositions and methods related to anti-egfr antibody drug conjugates; 2017-03-30.
Ref 18 Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.
Ref 19 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy.
Ref 20 Amatoxin derivatives.
Ref 21 Conjugates comprising self-immolative groups and methods related thereto.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.